Peripheral neuropathy secondary to docetaxel (Taxotere)

Neurology

Volumn 46, Issue 1, 1996, Pages 108-111

  New, P Z ^a,e   Jackson, C E ^a   Rinaldi, D ^c   Burris, H ^b   Barohn, R J ^d  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; HUMAN; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NEUROLOGIC EXAMINATION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY;

EID: 0029889373     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.1.108     Document Type: Article

References (20)

1. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-1259.
2. Donehower RC, Rowinsky EK. An overview of experience with taxol (paclitaxel) in the U.S.A. Cancer Treat Rev 1993;19: (suppl C):63-68.
3. Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc 1994;69:341-345.
4. Rowinsky E, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014.
5. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 1994;84:1781-1788.
6. Von Hoff D, Kuhn J, Irvin B, et al. Phase I clinical trial of RP56976 (Taxotere) given as a 6-hr infusion every three weeks [abstract]. Ann Oncol 1992:3(suppl 1):121.
7. Pazdur R, Kudelka AP, Kavanagh JJ, et al. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993; 19:351-386.
8. Bissery MC, Guenard D, Gueritte-Vogelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976; NSC 628503): a Taxol analogue. Cancer Res 1995;51:4845-4852.
9. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991; 83:288-291.
10. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989;38:368-373.
11. Kaplan JG, Einzig AI, Schaumberg HH. Taxol causes permanent large fiber peripheral nerve dysfunction: a lesson for preventive strategies. J Neurooncol 1993;16:105-107.
12. Van Gerven JM, Moll JW, Van den Bent MJ, et al. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994;30A:1074-1077.
13. Sahenk Z, Barohn RJ, New PZ, Mendell JR. Taxol neuropathy: electrodiagnostic and sural nerve findings. Arch Neurol 1994;51:726-729.
14. Neurotron, Inc. Neurometer CPT operating manual. Baltimore: Neurotron, 1989.
15. Barohn RJ, Gronseth GS, Leforce BR, et al. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol 1993;50:67-71.
16. Medical Research Council. Aids to the examination of the peripheral nervous system. London, England: Bailliere Tinndall, 1986.
17. Hilkens PHE, Verweij J, Stoter G, Vecht ChJ, van Putten WLJ, van den Bent MJ. Peripheral neurotoxicity induced by docetaxel. Neurology 1996;46:104-108.
18. Balmaceda P, Forsyth AD, Seidman P, et al. Peripheral neuropathy in patients receiving taxotere chemotherapy [abstract]. Ann Neurol 1993;34:313.
19. Barohn RJ, Kissel JT, Warmolt JR, Mendell JR. Chronic inflammatory demyelinating polyradiculopathy. Arch Neurol 1989;46:878-884.
20. Chaudhry V, Rowinsky EK, Sartorius SE, et al. Peripheral neuropathy from taxol and cisplatinum combination chemotherapy: clinical and electrophysiologic studies. Ann Neurol 1994;35:304-311.